Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have received an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $27.6667.

Several analysts have issued reports on the company. Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 19th. KeyCorp upped their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Morgan Stanley increased their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $24.00 to $30.00 in a research report on Thursday, January 22nd. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Friday, March 27th.

Elanco Animal Health Stock Up 0.1%

Shares of ELAN stock opened at $23.11 on Friday. The firm has a fifty day moving average of $24.56 and a 200-day moving average of $22.82. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60. Elanco Animal Health has a 12-month low of $8.02 and a 12-month high of $27.72. The company has a market capitalization of $11.49 billion, a price-to-earnings ratio of -48.14, a P/E/G ratio of 2.94 and a beta of 1.88.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The firm’s quarterly revenue was up 12.2% on a year-over-year basis. During the same period last year, the business posted $0.14 earnings per share. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, equities research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC grew its position in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after purchasing an additional 627 shares in the last quarter. SJS Investment Consulting Inc. increased its stake in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after buying an additional 1,333 shares during the last quarter. Root Financial Partners LLC lifted its position in Elanco Animal Health by 50.7% during the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock worth $40,000 after buying an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in Elanco Animal Health during the 4th quarter worth about $41,000. Finally, Huntington National Bank boosted its stake in shares of Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after buying an additional 1,087 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.